Tweeten Lutheran: Antipsychotic Safety Monitoring - MN

The resident, identified as R15 in inspection records, began taking olanzapine on the day of admission in October 2025. Federal inspectors found no evidence the facility ever conducted the mandatory tardive dyskinesia assessment designed to establish a baseline for monitoring abnormal involuntary movements.

R15 arrived with vascular dementia and moderate psychotic disturbances. The resident exhibited fluctuating disorganized thinking with daily behaviors, though these were not directed at other people. Medical records showed R15 was moderately cognitively impaired and could not complete standard assessments.

The medication regimen escalated significantly over the months. R15 initially received 5 milligrams of olanzapine each morning. By late October, staff increased the dose to twice daily. In early November, the facility doubled the total daily amount to 20 milligrams. By January 2026, R15 was receiving 15 milligrams daily in split doses.

The facility's own pharmacy review noted on admission day that R15 should receive tardive dyskinesia assessment "per physician" due to the antipsychotic prescription. No such assessment appears anywhere in the medical record.

Tardive dyskinesia causes involuntary movements that can become permanent. The condition typically affects the face, tongue, and limbs. Early detection through baseline assessments allows medical staff to monitor for the first signs of these potentially irreversible symptoms.

During the April inspection, nursing manager RN-A confirmed the facility's standard practice. Residents receiving antipsychotic medications undergo abnormal involuntary movement scale assessments on admission and every six months thereafter.

"RN-A confirmed R15 medical records did not indicate an AIMS assessment was done and confirmed R15 should have had a baseline AIMS assessment done upon admission," inspectors wrote.

The facility maintained a written policy specifically addressing this requirement. The February 2025 policy on psychotropic drug use stated baseline tardive dyskinesia assessments "will be completed with re-assessment every six months and as needed for antipsychotic medications."

R15 received multiple psychiatric medications simultaneously. Along with the olanzapine, medical records showed prescriptions for antianxiety and antidepressant medications. The combination therapy treated diagnoses including psychotic disorder and non-traumatic brain dysfunction.

The inspection occurred more than five months after R15's admission. By that point, the resident had been receiving antipsychotic medication for approximately 170 days without the safety monitoring the facility's own nursing manager described as standard practice.

Federal regulations require nursing homes to monitor residents for medication side effects, particularly with powerful psychiatric drugs known to cause movement disorders. The abnormal involuntary movement scale represents the standard tool for detecting early signs of tardive dyskinesia.

The missing baseline assessment meant staff had no reference point for detecting changes in R15's movement patterns. Without this initial measurement, medical providers cannot distinguish between existing conditions and new medication-induced symptoms.

Olanzapine belongs to a class of antipsychotic medications with documented risks for movement disorders. The drug requires careful monitoring in elderly patients, particularly those with dementia who may be more vulnerable to adverse effects.

The facility's pharmacy review process identified the monitoring requirement on the day of admission. However, the gap between policy and practice persisted for months while R15 continued receiving escalating doses of the medication.

Inspectors classified the violation as causing minimal harm or potential for actual harm to few residents. The finding represents one of multiple deficiencies identified during the April 2026 inspection at the 125-bed facility on 5th Avenue Southeast.

R15 remained at Tweeten Lutheran at the time of the inspection, still receiving the antipsychotic medication regimen that began without proper safety monitoring six months earlier.

Full Inspection Report

The details above represent a summary of key findings. View the complete inspection report for Tweeten Lutheran Health Care Center from 2026-04-02 including all violations, facility responses, and corrective action plans.

Additional Resources

• View all inspection reports for Tweeten Lutheran Health Care Center
• Browse all MN nursing home inspections